Dr. Mitchell's current research relates to the development of new therapies for hematologic malignancies. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. Recent studies have focused on the role of nucleolar proteins in cellular stress responses, including that induced by reactive oxygen species. She is also interested in the regulation of ribosomal RNA synthesis in hematopoietic stem and progenitor cells and in the role of dysregulated synthesis in bone marrow failure syndromes. in addition, her laboratory is involved in the translation of these studies into scientifically designed clinical trials.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals
AbbVie
Genentech
Amgen

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811